Radiation Sensitization of HNSCC Cells by the dual PI3K / mTOR Inhibitor BEZ235 as a function of the Cell Cycle

被引：0
|
作者：
Brandt, F. W. [1 ]
Balzer, V [1 ]
Dreffke, K. [1 ]
Wittig, A. [1 ,2 ]
Dikomey, E. [1 ,3 ]
Arenz, A. [1 ]
Schoetz, U. [1 ]
Engenhart-Cabillic, R. [1 ]
机构：
[1] Philipps Univ Marburg, Klin Strahlentherapie & Radioonkol, Marburg, Germany
[2] Univ Klinikum Jena, Klin Strahlentherapie & Radioonkol, Jena, Germany
[3] UKE Hamburg, Lab Strahlenbiol & Expt Radioonkol, Hamburg, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2018年 / 194卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P19-3-jD
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [21] Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer
    Dey, N.
    Wu, H.
    Sun, Y.
    De, P.
    Leyland-Jones, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S17 - S17
  • [22] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Wise-Draper, Trisha M.
    Moorthy, Ganesh
    Salkeni, Mohamad A.
    Karim, Nagla Abdel
    Thomas, Hala Elnakat
    Mercer, Carol A.
    Beg, M. Shalaan
    O'Gara, Sue
    Olowokure, Olugbenga
    Fathallah, Hassana
    Kozma, Sara C.
    Thomas, George
    Rixe, Olivier
    Desai, Pankaj
    Morris, John C.
    TARGETED ONCOLOGY, 2017, 12 (03) : 323 - 332
  • [23] SYNTHESIS AND PROCESS OPTIMIZATION OF PI3K/MTOR DUAL INHIBITOR NVP-BEZ235
    Xu, T. S.
    Lei, F.
    Tao, H.
    Li, J. Q.
    Zhang, Z. W.
    Wang, L. X.
    Xu, S.
    Zheng, P. W.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2016, 119 : 31 - 31
  • [24] NVP-BEZ235, a dual PI3K/mTOR inhibitor, may be effective for ovarian clear cell carcinoma cells
    Oishi, Tetsuro
    Itamochi, Hiroaki
    Nonaka, Michiko
    Sato, Seiya
    Naniwa, Jun
    Uegaki, Kazunori
    Sato, Shinya
    Shimada, Muneaki
    Terakawa, Naoki
    Kigawa, Junzo
    Harada, Tasuku
    CANCER RESEARCH, 2011, 71
  • [25] Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
    Yan Zhu
    Tiantian Tian
    Jianling Zou
    Qiwei Wang
    Zhongwu Li
    Yanyan Li
    Xijuan Liu
    Bin Dong
    Na Li
    Jing Gao
    Lin Shen
    BMC Cancer, 15
  • [26] The dual inhibitor BEZ235 radiosensitizes HNSCC cells due to impairment of the DSB repair
    Arenz, A.
    Balzer, V.
    Dreffke, K.
    Rieckmann, T.
    Koecher, S.
    Dikomey, E.
    Engenhart-Cabillic, R.
    Wittig, A.
    Schoetz, U.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S601 - S602
  • [27] Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
    Zhu, Yan
    Tian, Tiantian
    Zou, Jianling
    Wang, Qiwei
    Li, Zhongwu
    Li, Yanyan
    Liu, Xijuan
    Dong, Bin
    Li, Na
    Gao, Jing
    Shen, Lin
    BMC CANCER, 2015, 15
  • [28] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Trisha M. Wise-Draper
    Ganesh Moorthy
    Mohamad A. Salkeni
    Nagla Abdel Karim
    Hala Elnakat Thomas
    Carol A. Mercer
    M. Shalaan Beg
    Sue O’Gara
    Olugbenga Olowokure
    Hassana Fathallah
    Sara C. Kozma
    George Thomas
    Olivier Rixe
    Pankaj Desai
    John C. Morris
    Targeted Oncology, 2017, 12 : 323 - 332
  • [29] Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
    Zou, Hong
    Li, Li
    Carcedo, Ines Garcia
    Xu, Zhi Ping
    Monteiro, Michael
    Gu, Wenyi
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2016, 11 : 1947 - 1958
  • [30] The dual PI3K Inhibitor BEZ-235 causes synergistic Enhancement of Cisplatin and Radiation in HPV-negative and -positive HNSCC Cells
    Subtil, Florentine
    Groebner, Carolin
    Recknagel, Niklas
    Parplys, Ann Christin
    Arenz, Andrea
    Kohl, Sibylla
    Eberle, Fabian
    Dikomey, Ekkehard
    Engenhart-Cabillic, Rita
    Theiss, Ulrike
    STRAHLENTHERAPIE UND ONKOLOGIE, 2023, 199 : S26 - S27
12345